Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP001 Treg Cell Injection in Amyotrophic Lateral Sclerosis (Phase I/IIa)
ChiCTR2500108932Phase 2Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Sep 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sodium chlorite in amyotrophic lateral sclerosis (ALS) (5 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Types, severity, and incidence of adverse events (AEs) and serious adverse events (SAEs), Incidence and characteristics of dose-limiting toxicity (DLT) (Phase I only) and 1 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
sodium chlorite
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ChiCTR2500108932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108932.